Abstract
Ovarian cancer continues to present a significant health challenge with little progress being made over the past two decades in reducing the incidence and mortality. More recently, novel therapeutics have emerged as a potential way of improving outcomes for women with advanced ovarian cancer who harbor mutations in genes involved in homologous recombination (HR), most notably BRCA1 and BRCA2. In the United States, Olaparib, a PARP inhibitor, has been recently approved for ovarian cancer patients treated with three or more lines of prior chemotherapy who harbor germline mutations in BRCA1 or BRCA2. As a caveat to Olaparib’s FDA approval, BRACAnalysis CDx® was approved as a companion diagnostic test for women with ovarian cancer to determine their BRCA1/2 mutation status and eligibility for treatment. This review article will provide essential background information on hereditary breast and ovarian cancer (HBOC), describe the therapeutic mechanism of PARP inhibitors, and will chronicle the current and emerging homologous recombination deficiency (HRD) assays and their associated patents.
Keywords: Homologous recombination deficiency, gene mutations, synthetic lethality, genetic testing, BRCA1, BRCA2, olaparib, rucaparib, hereditary breast and ovarian cancer.
Graphical Abstract
Recent Patents on Biotechnology
Title:Recent Patents for Homologous Recombination Deficiency Assays Among Women with Ovarian Cancer
Volume: 9 Issue: 2
Author(s): Christopher J. LaFargue, Krishnansu S. Tewari and Gareth K. Forde
Affiliation:
Keywords: Homologous recombination deficiency, gene mutations, synthetic lethality, genetic testing, BRCA1, BRCA2, olaparib, rucaparib, hereditary breast and ovarian cancer.
Abstract: Ovarian cancer continues to present a significant health challenge with little progress being made over the past two decades in reducing the incidence and mortality. More recently, novel therapeutics have emerged as a potential way of improving outcomes for women with advanced ovarian cancer who harbor mutations in genes involved in homologous recombination (HR), most notably BRCA1 and BRCA2. In the United States, Olaparib, a PARP inhibitor, has been recently approved for ovarian cancer patients treated with three or more lines of prior chemotherapy who harbor germline mutations in BRCA1 or BRCA2. As a caveat to Olaparib’s FDA approval, BRACAnalysis CDx® was approved as a companion diagnostic test for women with ovarian cancer to determine their BRCA1/2 mutation status and eligibility for treatment. This review article will provide essential background information on hereditary breast and ovarian cancer (HBOC), describe the therapeutic mechanism of PARP inhibitors, and will chronicle the current and emerging homologous recombination deficiency (HRD) assays and their associated patents.
Export Options
About this article
Cite this article as:
LaFargue J. Christopher, Tewari S. Krishnansu and Forde K. Gareth, Recent Patents for Homologous Recombination Deficiency Assays Among Women with Ovarian Cancer, Recent Patents on Biotechnology 2015; 9 (2) . https://dx.doi.org/10.2174/187220830902160308184054
DOI https://dx.doi.org/10.2174/187220830902160308184054 |
Print ISSN 1872-2083 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4012 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Patents on Osteoinductive Molecules for Bone Tissue Engineering
Recent Patents on Biomedical Engineering (Discontinued) Ellagic Acid Increases Osteocalcin and Alkaline Phosphatase After Tooth Extraction in Nicotinic-Treated Rats
Current Pharmaceutical Design Anticancer Potential of Ginger: Mechanistic and Pharmaceutical Aspects
Current Pharmaceutical Design Micro-/Nano-Scale Biointerfaces, Mechanical Coupling and Cancer Therapy
Current Topics in Medicinal Chemistry Nanotechnology in the Management of Bone Diseases and as Regenerative Medicine
Current Nanoscience Lipid Nanoparticles to Deliver miRNA in Cancer
Current Pharmaceutical Biotechnology NK Cell, Monocyte and Non T Cell Biomarkers as Prognostic Indicators in Cancer Immunotherapy
Current Cancer Therapy Reviews Optical and Multimodal Peptide-Based Probes for In Vivo Molecular Imaging
Anti-Cancer Agents in Medicinal Chemistry Opportunities of Finding Novel Anti-Infective Agents from Plant Cell Cultures
Current Medicinal Chemistry - Anti-Infective Agents Membrane Permeable Lipophilic Cations as Mitochondrial Directing Groups
Current Topics in Medicinal Chemistry Two Novel GPER Agonists Induce Gene Expression Changes and Growth Effects in Cancer Cells
Current Cancer Drug Targets Bone Modulating Bioactive Natural Compounds: Review
Current Bioactive Compounds Multi- and Inter-Disciplinary Science in Personalized Delivery of Stem Cells for Tissue Repair
Current Stem Cell Research & Therapy Sanguinarine: A Double-Edged Sword of Anticancer and Carcinogenesis and Its Future Application Prospect
Anti-Cancer Agents in Medicinal Chemistry Cytochrome P450 Gene Polymorphism and Cancer
Current Drug Metabolism Osteosarcoma of the Jaws: A Literature Review
Current Medical Imaging Forensic DNA Phenotyping in Criminal Investigations and Criminal Courts: Assessing and Mitigating the Dilemmas Inherent in the Science
Recent Advances in DNA & Gene Sequences (Discontinued) Metal Containing Cytostatics and Their Interaction with Cellular Thiol Compounds Causing Chemoresistance
Anti-Cancer Agents in Medicinal Chemistry High Throughput Screening of Normal and Neoplastic Tissue Samples
Combinatorial Chemistry & High Throughput Screening Antibody Based EpCAM Targeted Therapy of Cancer, Review and Update
Current Cancer Drug Targets